These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

596 related items for PubMed ID: 15122540

  • 1. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
    Salazar Tortolero G, Wix Ramos R, Salazar Aladrén P, Jiménez León JC.
    Rev Neurol; ; 38(8):715-9. PubMed ID: 15122540
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
    Ziegler M, Castro-Caldas A, Del Signore S, Rascol O.
    Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
    Suwantamee J, Nidhinandana S, Srisuwananukorn S, Laptikultham S, Pisarnpong A, Chankrachang S, Bundhukul A.
    J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
    [Abstract] [Full Text] [Related]

  • 4. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A, Delwaide P, Jost W, Merello M, Williams A, Lamberti P, Aguilar M, Del Signore S, Cesaro P, Parkinson-Control Study Group.
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [Abstract] [Full Text] [Related]

  • 5. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
    Rascol O, Dubois B, Caldas AC, Senn S, Del Signore S, Lees A, Parkinson REGAIN Study Group.
    Mov Disord; 2006 Dec; 21(12):2110-5. PubMed ID: 17013922
    [Abstract] [Full Text] [Related]

  • 6. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [Abstract] [Full Text] [Related]

  • 7. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P, Findley LJ, Jeffs JA, Pearce RK, Bain PG.
    Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
    [Abstract] [Full Text] [Related]

  • 8. [Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].
    Fedorova NV.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003 Feb; 103(11):21-4. PubMed ID: 14681961
    [Abstract] [Full Text] [Related]

  • 9. High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study.
    Arnold G, Gasser T, Storch A, Lipp A, Kupsch A, Hundemer HP, Schwarz J.
    Arch Gerontol Geriatr; 2005 Feb; 41(3):239-53. PubMed ID: 16029905
    [Abstract] [Full Text] [Related]

  • 10. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.
    Giménez-Roldán S, Tolosa E, Burguera JA, Chacón J, Liaño H, Forcadell F.
    Clin Neuropharmacol; 1997 Feb; 20(1):67-76. PubMed ID: 9037575
    [Abstract] [Full Text] [Related]

  • 11. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH, Klasser M, Reichmann H.
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [Abstract] [Full Text] [Related]

  • 12. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH, Ha JH, Cho IS, Lee MC.
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [Abstract] [Full Text] [Related]

  • 13. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP, Boas J.
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [Abstract] [Full Text] [Related]

  • 14. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS, Kirby L, Kumar D, Cullen EI, Pratt RD, Hahne WA.
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [Abstract] [Full Text] [Related]

  • 15. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
    Metman LV, Blanchet PJ, de Jong D, Mouradian MM, Chase TN.
    Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
    [Abstract] [Full Text] [Related]

  • 16. Randomized trial of pallidotomy versus medical therapy for Parkinson's disease.
    Vitek JL, Bakay RA, Freeman A, Evatt M, Green J, McDonald W, Haber M, Barnhart H, Wahlay N, Triche S, Mewes K, Chockkan V, Zhang JY, DeLong MR.
    Ann Neurol; 2003 May; 53(5):558-69. PubMed ID: 12730989
    [Abstract] [Full Text] [Related]

  • 17. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil.
    Thobois S, Lhommée E, Klinger H, Ardouin C, Schmitt E, Bichon A, Kistner A, Castrioto A, Xie J, Fraix V, Pelissier P, Chabardes S, Mertens P, Quesada JL, Bosson JL, Pollak P, Broussolle E, Krack P.
    Brain; 2013 May; 136(Pt 5):1568-77. PubMed ID: 23543483
    [Abstract] [Full Text] [Related]

  • 18. [A comparative study of the effect of bromocriptine and pergolide on Parkinson disease].
    de Yébenes JG, García-Ruiz PJ, Sánchez-Pernaute R.
    Rev Neurol; 1997 Sep; 25(145):1343-5. PubMed ID: 9377286
    [Abstract] [Full Text] [Related]

  • 19. [Piribedil, dopaminergic agonist. Prolonged clinical and electrophysiological study in 60 parkinsonian patients (author's transl)].
    Truelle JL, Chanelet J, Bastard J, Six P, Emile J.
    Nouv Presse Med; 1977 Oct 08; 6(33):2987-90. PubMed ID: 22844
    [Abstract] [Full Text] [Related]

  • 20. End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study.
    Simon N, Micallef J, Reynier JC, Lesourd M, Witjas T, Alicherif A, Azulay JP, Blin O.
    Mov Disord; 2005 Jul 08; 20(7):803-9. PubMed ID: 15726579
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.